Germany: Leaked Pricing Measures Could Have ‘Drastic’ Consequences For Orphans
'Dangerous’ new measures outlined in a leaked bill would be a disaster for orphan drugs and lead to companies opting out of the German market, says one industry executive.
You may also be interested in...
New cost saving measures in Germany include mandatory volume agreements that will prompt companies to take more account of the size of the populations targeted by their products. Meanwhile, a new link between product wastage and prices should encourage some companies to think about their pack sizes.
A new law aimed at limiting drug spending in Germany will mean that only companies with new products that offer high levels of added benefit will have full flexibility to negotiate prices.
Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.